

JUL 29 2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|  |   |             |                     |
|--|---|-------------|---------------------|
| In re United States Patent Application of: | ) | Docket No.: | 4354-110            |
| Applicants:                                | ) | Conf. No.:  | 4322                |
| CABANA, Bernard E., et                     | ) |             |                     |
| al.  | ) |             |                     |
| Application No.:                           | ) | Art Unit:   | 1614                |
| 10/668,792                                 | ) |             |                     |
| Date Filed:                                | ) | Examiner:   | Spivack, Phyllis G. |
| September 23, 2003                         | ) |             |                     |
| Title:                                     | ) | Customer    |                     |
| RIFALAZIL                                  | ) | No.:        | 23448               |
| COMPOSITIONS AND                           | ) |             |                     |
| THERAPEUTIC                                | ) |             |                     |
| REGIMENS                                   | ) |             |                     |

FACSIMILE TRANSMISSION CERTIFICATEATTN: Examiner Spivack

Fax No. (571) 273-8300

I hereby certify that this document, along with any enclosures identified herein, is being filed in the United States Patent and Trademark Office, via facsimile transmission addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, and transmitted on the date specified below, to United States Patent and Trademark Office facsimile transmission number (571)273-8300.

9

Number of Pages

  
Kate Pope

July 29, 2010

Date

RESPONSE TO OFFICE ACTION IN U.S. PATENT APPLICATION NO.  
10/668,792

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The following responds to the Office Action mailed in connection with the above-identified application on March 31, 2010. Please amend the Abstract as set out in

4354-110

**Section I (Amendments to the Abstract)**, beginning on page 3 hereof. Please amend the claims of the above-identified patent application as set out in **Section II (Amendments to the Claims)**, beginning on page 4 hereof. Remarks concerning the amendments to the claims and the substance of the Office Action are set out in **Section III (Remarks)** hereof.